Nordic Nanovector ASA
OSE:NANOV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Nordic Nanovector ASA
Other Non-Cash Items
Nordic Nanovector ASA
Other Non-Cash Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Non-Cash Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
N
|
Nordic Nanovector ASA
OSE:NANOV
|
Other Non-Cash Items
-kr11.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
L
|
Lytix Biopharma AS
OSE:LYTIX
|
Other Non-Cash Items
kr878k
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
|
Arcticzymes Technologies ASA
OSE:AZT
|
Other Non-Cash Items
kr1.6m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
1%
|
CAGR 10-Years
8%
|
|
|
N
|
Nykode Therapeutics ASA
OSE:NYKD
|
Other Non-Cash Items
-$11m
|
CAGR 3-Years
-68%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Circio Holding ASA
OSE:CRNA
|
Other Non-Cash Items
kr5.8m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
0%
|
|
|
T
|
Thor Medical ASA
OSE:TRMED
|
Other Non-Cash Items
-kr2.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-3%
|
|
Nordic Nanovector ASA
Glance View
Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The company is headquartered in Oslo, Oslo and currently employs 40 full-time employees. The company went IPO on 2014-07-07. The company is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product candidate is Betalutin, comprising a tumor-seeking anti-CD37 antibody conjugated to a low intensity radionuclide (Lutetium 177). The company is designed improve treatment of Non-Hodgkin Lymphoma (NHL) and advanced through clinical development. Additionally, the Company is engaged in the development of its Antibody-Radionuclide-Conjugate (ARC) portfolio to treat various selected cancer indications. The company has two subsidiaries, Nordic Nanovector GmbH and Nordic Nanovector Ltd.
See Also
What is Nordic Nanovector ASA's Other Non-Cash Items?
Other Non-Cash Items
-11.7m
NOK
Based on the financial report for Dec 31, 2022, Nordic Nanovector ASA's Other Non-Cash Items amounts to -11.7m NOK.
